1.Comparative study of the efficacy of lateral lumbar interbody fusion combined with anterolateral screw fixation or bilateral pedicle screw fixation in the treatment of lumbar degenerative diseases
Bopei ZHU ; Longheng QIU ; Zhenkai LOU ; Hengtao HE ; Jing HUANG ; Yu XIAO ; Chenyuan GUO ; Bing WANG
Chinese Journal of Spine and Spinal Cord 2025;35(4):390-398,407
Objectives:To compare the efficacy and imaging parameters of lateral lumbar interbody fusion(LLIF)combined with anterolateral screw fixation(AF)or bilateral pedicle screw fixation(BPSF)in the treatment of lumbar degenerative disease(LDD).Methods:A retrospective study was conducted on 100 patients with single-segment LDD who underwent LLIF-AF or LLIF-BPSF treatment at the First Affiliated Hospital of Kunming Medical University between December 2019 and December 2021.The patients were divided into the AF group(50 cases)and the BPSF group(50 cases).There was no statistical difference in the general informa-tion such as gender,age,and body mass index(BMI)between the two groups(P>0.05).The perioperative data(length of hospital stay,operative time,intraoperative blood loss);Pre-operative,postoperative 7d,postoperative 6 months' visual analog scale(VAS)scores for low back and leg pain,Oswestry disablity index(ODI),imaging parameters such as disc height(DH),foraminal height(FH),cross-sectional area(CSA),as well as surgical complications were collected and analyzed,and the risk factors for intervertebral subsidence and non-fusion of fusion device were explored.Results:AF group was better than BPSF group in operative time,intraoperative blood loss,and hospital stay[125.0±26.6min vs 221.6±52.2min,25.0mL(20.0-50.0mL)vs 100.0mL(90.0-150.0mL),12.5±4.8d vs 14.9±4.6d],and the differences were statistically significant(P<0.05).For the low back and leg pain VAS scores and ODI,as well as DH,FH,and CSA,the postoperative 7d and 6 months'values were signiticantly improved than before operation in both groups(P<0.05),while no statistically significant differences were found between groups at the same time points(P>0.05).Intervertebral subsidence occurred in 12 patients in each group,and there was no statistically significant difference between the two groups.There were statistically significant differences in BMI and QCT between the AF and BPSF groups of patients with subsidence of the intervertebral space and those without subsidence at 6 months after operation;There were statistically significant differences in QCT between the two groups of patients with non-fusion and fusion of the fusion device;BMI≥28kg/m2 and QCT<80mg/cm3 were the independent risk factors for intervertebral subsidence in AF group,but not in the BPSF group;QCT<80mg/cm3 was the independent risk facors for non-fusion of fusion device in both AF and BPSF groups.Conclusions:LLIF combined with AF or BPSF are both reliable methods for treating LDD.For patients with a high body weight of BMI≥28kg/m2 or decreased bone density of QCT<80mg/cm3,BPSF internal fixation can provide stronger mechanical stability to the spine,reducing the incidence of postoperative disc space collapse or fusion device non-union;On the contrary,AF internal fixation has shorter operative time and hospital stay,less intraoperative blood loss,which can be considered as a priority.
2.Comparative study of the efficacy of lateral lumbar interbody fusion combined with anterolateral screw fixation or bilateral pedicle screw fixation in the treatment of lumbar degenerative diseases
Bopei ZHU ; Longheng QIU ; Zhenkai LOU ; Hengtao HE ; Jing HUANG ; Yu XIAO ; Chenyuan GUO ; Bing WANG
Chinese Journal of Spine and Spinal Cord 2025;35(4):390-398,407
Objectives:To compare the efficacy and imaging parameters of lateral lumbar interbody fusion(LLIF)combined with anterolateral screw fixation(AF)or bilateral pedicle screw fixation(BPSF)in the treatment of lumbar degenerative disease(LDD).Methods:A retrospective study was conducted on 100 patients with single-segment LDD who underwent LLIF-AF or LLIF-BPSF treatment at the First Affiliated Hospital of Kunming Medical University between December 2019 and December 2021.The patients were divided into the AF group(50 cases)and the BPSF group(50 cases).There was no statistical difference in the general informa-tion such as gender,age,and body mass index(BMI)between the two groups(P>0.05).The perioperative data(length of hospital stay,operative time,intraoperative blood loss);Pre-operative,postoperative 7d,postoperative 6 months' visual analog scale(VAS)scores for low back and leg pain,Oswestry disablity index(ODI),imaging parameters such as disc height(DH),foraminal height(FH),cross-sectional area(CSA),as well as surgical complications were collected and analyzed,and the risk factors for intervertebral subsidence and non-fusion of fusion device were explored.Results:AF group was better than BPSF group in operative time,intraoperative blood loss,and hospital stay[125.0±26.6min vs 221.6±52.2min,25.0mL(20.0-50.0mL)vs 100.0mL(90.0-150.0mL),12.5±4.8d vs 14.9±4.6d],and the differences were statistically significant(P<0.05).For the low back and leg pain VAS scores and ODI,as well as DH,FH,and CSA,the postoperative 7d and 6 months'values were signiticantly improved than before operation in both groups(P<0.05),while no statistically significant differences were found between groups at the same time points(P>0.05).Intervertebral subsidence occurred in 12 patients in each group,and there was no statistically significant difference between the two groups.There were statistically significant differences in BMI and QCT between the AF and BPSF groups of patients with subsidence of the intervertebral space and those without subsidence at 6 months after operation;There were statistically significant differences in QCT between the two groups of patients with non-fusion and fusion of the fusion device;BMI≥28kg/m2 and QCT<80mg/cm3 were the independent risk factors for intervertebral subsidence in AF group,but not in the BPSF group;QCT<80mg/cm3 was the independent risk facors for non-fusion of fusion device in both AF and BPSF groups.Conclusions:LLIF combined with AF or BPSF are both reliable methods for treating LDD.For patients with a high body weight of BMI≥28kg/m2 or decreased bone density of QCT<80mg/cm3,BPSF internal fixation can provide stronger mechanical stability to the spine,reducing the incidence of postoperative disc space collapse or fusion device non-union;On the contrary,AF internal fixation has shorter operative time and hospital stay,less intraoperative blood loss,which can be considered as a priority.
3.Clinical study of prophylactic hyperthermic intraperitoneal chemotherapy for colorectal cancer
Li FU ; Ren BAOQING ; Guo CHENYUAN ; Huang BO
Chinese Journal of Clinical Oncology 2024;51(24):1267-1272
Objective:To study the safety and efficacy of prophylactic hyperthermic intraperitoneal chemotherapy(HIPEC)in patients with colorectal cancer(CRC).Methods:The data of 180 patients with CRC at Shanxi Provincial People's Hospital from February 2019 to February 2022 were retrospectively collected and assigned into HIPEC and control groups.Among these patients,53 patients were in the HIPEC group and 127 patients were in the control group.Proensity score matching(PSM)using 1:1 ratio to balance the confounding factors between the two groups and successfully matched to 48 pairs of patients.Results:No significant difference was observed in the occurrence of postoper-ative complications between the HIPEC and control groups(P>0.05).After 2 years of follow-up,a significant decrease was noted in preoper-ative and postoperative carcinoembryonic antigen(CEA)levels in both groups(P<0.05).The overall metastasis rate for early postoperative CRC was 17.65%,which differed significantly between the HIPEC and control groups(9.30%vs.26.19%,P<0.05).Conclusions:HIPEC is safe and feasible for CRC surgery and does not increase the occurrence of postoperative complications.As a perfusion solution,lobaplatin exhib-its minimal toxicity and no apparent side effects.Intraoperative HIPEC can effectively prevent early metastasis of CRC,which is conducive to improved patient prognosis.
4.Clinical study of prophylactic hyperthermic intraperitoneal chemotherapy for colorectal cancer
Li FU ; Ren BAOQING ; Guo CHENYUAN ; Huang BO
Chinese Journal of Clinical Oncology 2024;51(24):1267-1272
Objective:To study the safety and efficacy of prophylactic hyperthermic intraperitoneal chemotherapy(HIPEC)in patients with colorectal cancer(CRC).Methods:The data of 180 patients with CRC at Shanxi Provincial People's Hospital from February 2019 to February 2022 were retrospectively collected and assigned into HIPEC and control groups.Among these patients,53 patients were in the HIPEC group and 127 patients were in the control group.Proensity score matching(PSM)using 1:1 ratio to balance the confounding factors between the two groups and successfully matched to 48 pairs of patients.Results:No significant difference was observed in the occurrence of postoper-ative complications between the HIPEC and control groups(P>0.05).After 2 years of follow-up,a significant decrease was noted in preoper-ative and postoperative carcinoembryonic antigen(CEA)levels in both groups(P<0.05).The overall metastasis rate for early postoperative CRC was 17.65%,which differed significantly between the HIPEC and control groups(9.30%vs.26.19%,P<0.05).Conclusions:HIPEC is safe and feasible for CRC surgery and does not increase the occurrence of postoperative complications.As a perfusion solution,lobaplatin exhib-its minimal toxicity and no apparent side effects.Intraoperative HIPEC can effectively prevent early metastasis of CRC,which is conducive to improved patient prognosis.
5.Research progress of hyperthermic intraperitoneal chemotherapy in the treatment of colorectal cancer
Fu LI ; Chenyuan GUO ; Bo HUANG
International Journal of Surgery 2023;50(5):354-360
Colorectal cancer is a common digestive system malignant tumor in the world, its incidence and mortality rate is in the forefront, with the social progress and the change of diet structure, the incidence of colorectal cancer is gradually increasing, and there is a trend of younger age. Among them, peritoneal metastasis is the main cause of death in patients with colorectal cancer. Non-surgical treatment has been used in the past, but the prognosis is poor. How to treat and prevent peritoneal metastasis in colorectal cancer patients and improve the prognosis of such patients as much as possible is a question worth our in-depth study. The hyperthermic intraperitoneal chemotherapy provides a new direction for the treatment of colorectal cancer patients, usually combined with surgical treatment, and co-applied in the clinic as a new treatment model. This article reviews the treatment mode of hyperthermic intraperitoneal chemotherapy, the choice of drugs, and the progress of research in the treatment and prevention of peritoneal metastasis in colorectal cancer.

Result Analysis
Print
Save
E-mail